Personalized vaccine with chemo and immunotherapy for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of a personalized cancer vaccine (made from your own tumor), chemotherapy, and an immunotherapy drug (like pembrolizumab) for people with triple-negative breast cancer that has spread or can't be removed and has stopped responding to standard treatment. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 71 years old.
- You have triple-negative breast cancer that has spread or can't be removed with surgery, and it tested negative for certain markers (PD-L1 and BRCA).
- You've already tried an antibody-drug conjugate (ADC) treatment and your cancer got worse.
- You must send a small sample of your tumor tissue (about 200 mg) to the study company for analysis.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You have not had immunotherapy (like PD-1/PD-L1 inhibitors) or steroids recently, and you don't have certain health conditions like autoimmune diseases or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
This trial is for people with early triple-negative breast cancer who had a strong response to chemotherapy combined with pembrolizumab before surgery. It aims to find the best way to continue using pembrolizumab after surgery to reduce the risk of cancer coming back.
This trial tests a combination of two drugs (camrelizumab and pirfenidone) with chemotherapy to see if it can help people with advanced triple-negative breast cancer. It may offer a new treatment option for those whose cancer has progressed after initial treatment.
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
This trial tests a personalized cancer vaccine (NECVAX-NEO1) given along with standard chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. The vaccine is customized to target specific mutations in your tumor, aiming to boost your immune system and improve treatment outcomes.
This trial tests a personalized cancer vaccine designed to train your immune system to fight triple negative breast cancer. It is for people who are already receiving or about to receive the standard KEYNOTE 522 treatment, and the vaccine is given after a few months of that treatment.
Hear when a new Triple-Negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.